The phosphoinositide-3 kinase-AKT-mammalian target of rapamycin (mTOR) pathway has been identified as a candidate pathway in bladder cancer progression in several recent clinicopathological studies [8,9]. Here, MTOR is linked to urinary bladder carcinoma.